The news is directly about CytomX Therapeutics. The analyst from Wedbush maintains a Neutral rating, indicating no change in the company's outlook. However, the increase in price target from $2 to $3 suggests a positive sentiment towards the company's stock. This could potentially lead to a slight increase in the stock price, but given the Neutral rating, the impact is not expected to be significant.